左乳腺癌3D-CRT中心脏亚结构剂量分布:平均心脏剂量与平均左心室剂量预测准确性比较
本研究纳入55例左侧乳腺癌患者(39例淋巴结阳性、16例阴性),均接受3D-CRT辅助全乳照射,评估心脏亚结构剂量分布并比较MHD与MLVD对亚结构剂量的预测准确性。结果显示LADCA受照剂量最高(淋巴结阳性15.6 Gy、阴性13.2 Gy),MLVD预测准确性略优于MHD,尤其在淋巴结阳性患者中。
要点
- 左乳腺癌3D-CRT中心脏亚结构剂量分布不均,LADCA受量最高。
- 淋巴结阳性患者LADCA平均剂量15.6 Gy,阴性患者13.2 Gy。
- MLVD对LADCA剂量的预测准确性略优于MHD,淋巴结阳性者更明显。
核心结论
- 左乳腺癌3D-CRT中心脏亚结构受照不均,LADCA平均剂量最高,其次为LV。
- MLVD对关键亚结构剂量的预测准确性优于MHD,尤其在淋巴结阳性患者中。
研究设计与样本
- 本研究纳入55例左侧乳腺癌患者,其中淋巴结阳性39例、阴性16例,均接受3D-CRT辅助全乳照射。
- 勾画心脏、心室、心房、右冠状动脉(RC)、左前降支冠状动脉(LADCA)和左回旋支(LCx)动脉,评估剂量分布。
- 采用Pearson相关和线性回归分析评估心脏亚结构剂量与MHD/MLVD的关系。
主要发现
- LADCA平均剂量在淋巴结阳性患者为15.6 Gy,在淋巴结阴性患者为13.2 Gy。
- 淋巴结阳性患者中,MHD与LADCA的R²为0.40(p < 0.001),MLVD与LADCA的R²为0.45(p < 0.001)。
- 淋巴结阴性患者中,MHD与LADCA的R²为0.27(p < 0.001),MLVD与LADCA的R²为0.30(p < 0.03)。
- 淋巴结阳性患者中,MHD与LADCA的r=0.63(p < 0.001),MLVD与LADCA的r=0.67(p < 0.001)。
- 淋巴结阴性患者中,MHD与LADCA的r=0.52(p < 0.001),MLVD与LADCA的r=0.54(p < 0.001)。
关键数值与推荐
- 淋巴结阳性患者LADCA平均剂量15.6 Gy,淋巴结阴性患者13.2 Gy。
- 淋巴结阳性患者MHD预测LADCA的R²=0.40(p < 0.001),MLVD预测LADCA的R²=0.45(p < 0.001)。
- 淋巴结阴性患者MHD预测LADCA的R²=0.27(p < 0.001),MLVD预测LADCA的R²=0.30(p < 0.03)。
临床怎么用
- 在左乳腺癌3D-CRT中可关注心脏亚结构剂量,尤其是LADCA的受照剂量。
- MLVD可能较MHD更准确地预测心脏亚结构剂量,尤其在淋巴结阳性患者中。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Cardiotoxicity is a concern, especially in left breast cancer (BC) radiotherapy (RT), and accurate dosimetry is essential for minimizing cardiac exposure. This study evaluated the radiation exposure of cardiac substructures in node-positive and node-negative BC patients who underwent three-dimensional conformal therapy (3D-CRT) and compared the predictive accuracy of mean heart dose (MHD) and mean left ventricular dose (MLVD) in estimating dose distribution to cardiac substructures. MATERIALS AND METHODS: This study included 55 patients with left-sided breast cancer, comprising 39 with node-positive and 16 with node-negative disease. All underwent adjuvant whole-breast irradiation using 3D-CRT. The heart, ventricles, atria, right coronary (RC), left anterior descending coronary (LADCA), and left circumflex (LCx) arteries were contoured. Dosimetric distributions were evaluated, and Pearson's correlation and linear regression analyses were used to assess the relationship between cardiac substructures. RESULTS: The distribution of doses to cardiac substructures was heterogeneous, with LADCA receiving the highest doses: 15.6 Gy in node-positive and 13.2 Gy in node-negative breast cancer patients. Linear regression analysis revealed a weak to moderate predictive ability of MHD/MLVD to predict doses received by the cardiac substructure in both groups, with MLVD demonstrating marginally better results. For node-positive patients, the analysis revealed an R² of 0.40 (p < 0.001) for the association between MHD and LADCA and an R² of 0.45 (p < 0.001) for MLVD and LADCA. In node-negative patients, the R² values were 0.27 (p < 0.001) for MHD versus LADCA and 0.30 (p < 0.03) for MLVD versus LADCA. Pearson's correlation analysis for node-positive patients indicated r = 0.63 (p < 0.001) for MHD versus LADCA and r = 0.67 (p < 0.001) for MLVD versus LADCA. For node-negative patients, the correlation coefficients were r = 0.52 (p < 0.001) for MHD versus LADCA and r = 0.54 (p < 0.001) for MLVD versus LADCA. CONCLUSION: Radiation exposure to cardiac substructures during 3D-CRT for left breast cancer was heterogeneous, with the LADCA receiving the highest mean dose, followed by the LV. MLVD demonstrated superior predictive accuracy over mean heart dose (MHD) for estimating doses to critical substructures, particularly in node-positive patients.
引用
- Nuruddeen MG, A Karim NK, A/L Appalanaido GK, et al. Cardiac substructure dose distributions in node-positive and node-negative breast cancer patients undergoing 3D-CRT: comparing the predictive accuracy of mean heart dose and mean left ventricular dose. Radiat Oncol. 2025. PMID: 40301974. doi:10.1186/s13014-025-02607-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。